Focused On-demand Library for Beta-enolase

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P13929

UPID:
ENOB_HUMAN

ALTERNATIVE NAMES:
2-phospho-D-glycerate hydro-lyase; Enolase 3; Muscle-specific enolase; Skeletal muscle enolase

ALTERNATIVE UPACC:
P13929; B4DUI6; B4DUM6; D3DTL2; E7ENK8; Q96AE2

BACKGROUND:
The enzyme Beta-enolase, with aliases such as Enolase 3 and Muscle-specific enolase, is integral to the glycolytic pathway, facilitating the transformation of 2-phosphoglycerate into phosphoenolpyruvate. It is essential for the proper development and repair of striated muscles, underscoring its significance in muscle physiology.

THERAPEUTIC SIGNIFICANCE:
Impairments in Beta-enolase activity are implicated in Glycogen storage disease 13, manifesting as exercise-induced pain, generalized muscle weakness, and altered muscle biochemistry. The exploration of Beta-enolase's function holds promise for innovative treatments targeting this genetic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.